Neural Ensembles & Used Substances (NExUS) Collaboratory: Building a Multimodal Inventory of Cell Ensembles Encoding the Effects of Addictive Substances (U01 Clinical Trial Not Allowed) | RFA DA 28 013

Frequently Asked Questions (FAQ)

What is this funding opportunity?

This is a National Institute on Drug Abuse (NIDA) funding opportunity to renew and expand the Neural Ensembles and Used Substances (NExUS) Collaboratory. It is a coordinated research effort aimed at building a systematic, scalable, and broadly useful resource for understanding how substance use experiences and addiction-relevant neurobehavioral states are represented in the brain at the level of neural populations (ensembles).

What is the main scientific focus of NExUS?

NExUS focuses on neural ensembles (groups of cells) rather than single neurons. The goal is to identify and characterize populations of cells whose activity patterns encode substance-related states and experiences relevant to substance use disorders (SUD), such as intoxication, craving, and dependence, and to map how those ensemble patterns relate to behavior and internal state.

What does NIDA mean by "neural ensembles" in this context?

In this opportunity, neural ensembles refer to groups of neurons or cells whose coordinated activity patterns represent meaningful substance-related experiences or neurobehavioral states. The initiative emphasizes identifying, mapping, and analyzing these ensembles as population-level representations rather than interpreting single-cell signals in isolation.

What kinds of addiction-related states are specifically mentioned?

The description specifically mentions intoxication, craving, and dependence as examples of behavioral and internal states that matter for substance use disorders and that the program aims to relate to population activity patterns.

What is the overall goal or "deliverable" NIDA is looking for?

NIDA is explicitly aiming for a database-like output: a comprehensive multimodal inventory that organizes evidence about the same underlying neural ensembles so the broader research community can support cross-study comparisons and test mechanistic hypotheses about how population activity patterns relate to addiction-relevant states.

What does "multimodal inventory" mean here?

It means compiling and integrating multiple types of evidence about neural ensembles into a unified resource. The opportunity mentions examples such as functional activity signatures, anatomical and circuit mapping, and cell-type or molecular profiles, organized to enable comparisons and hypothesis testing across studies.

Is method development and standardization a major requirement?

Yes. A major emphasis is method development and standardization at scale. Applicants are expected to propose approaches that can reliably identify, map, and analyze neuronal ensembles responding to used substances, and integrate findings into a comprehensive, organized inventory.

What does "at scale" imply for this program?

Based on the description, "at scale" implies approaches that are systematic and scalable, with standardization that supports broad use, coordination across efforts, and cross-study comparisons (rather than one-off methods or purely descriptive datasets).

What is the funding mechanism for this opportunity?

The award mechanism is a cooperative agreement (U01). This indicates that NIDA/NIH expects substantial scientific and programmatic involvement during the project, with stronger expectations around coordination, common standards, data sharing, and collaboration compared to many investigator-initiated grants.

How is a U01 cooperative agreement different from a typical grant?

In general terms as stated in the opportunity summary, cooperative agreements typically come with stronger expectations for coordination, common standards, data sharing, and collaboration across funded teams, along with substantial NIH involvement in the project.

Are clinical trials allowed under this opportunity?

No. The notice states "Clinical Trial Not Allowed," meaning the proposed work cannot include a clinical trial as defined by NIH policy and should be structured accordingly.

Who is eligible to apply?

Eligibility is broad and includes many U.S. organization types: state and local governments, tribal governments and organizations, public and private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations other than small businesses, and small businesses. The notice also includes "Others" as allowed under NIH rules.

Are for-profit organizations eligible?

Yes. The eligibility list includes for-profit organizations other than small businesses, and it separately includes small businesses as eligible.

Can non-U.S. (foreign) organizations apply?

Yes. International participation is permitted in multiple forms, including that non-U.S. entities (foreign organizations) may apply, non-U.S. components of U.S. organizations are allowed, and foreign components (as defined in the NIH Grants Policy Statement) are allowed.

Are foreign subawards or foreign subcontracts allowed?

No. Under this specific NOFO, NIH will not issue awards to projects that include foreign subawards or subcontracts. Applications proposing foreign subawards/subcontracts are considered noncompliant and will not be reviewed for funding.

If foreign subawards/subcontracts are not allowed, is any international involvement still possible?

Yes. The description notes that this restriction does not block all international involvement. Examples that can still be acceptable include unfunded collaborations, foreign components in the NIH sense, paid foreign consultants, and purchasing unique equipment or supplies from foreign vendors. The key constraint is that the budget cannot include foreign subaward/subcontract arrangements unless applying under a NOFO specifically designated for funded international collaborations.

What is the Funding Opportunity Number for this program?

The Funding Opportunity Number is RFA-DA-28-013.

What is the CFDA number listed for this opportunity?

The CFDA number listed is 93.279.

Which agency is sponsoring this opportunity?

NIDA (the National Institute on Drug Abuse), within the National Institutes of Health (NIH), is the sponsoring agency.

How many awards does NIDA expect to make?

NIDA anticipates making about four awards.

What is the application due date (closing date)?

The original closing date listed is February 8, 2027.

Is there an award ceiling or budget cap listed in the provided information?

No. The notice lists an award ceiling as not specified in the provided text. Applicants would need to consult the full NOFO for budget limits, project period details, and required application components.

What additional details should applicants expect to find in the full NOFO?

Based on the information provided, applicants should consult the full NOFO for items not specified here, including budget limits, project period details, and the specific required components of an application, such as expectations for collaboration, governance, data standards, and resource sharing that typically accompany a collaboratory-style program.

Is this opportunity focused on descriptive neuroscience data, or hypothesis testing as well?

The initiative is described as aiming for a database-like output that is not just descriptive. It is intended to enable researchers to evaluate mechanistic hypotheses about how particular population activity patterns relate to specific behavioral states relevant to addiction.

What does it mean that the opportunity is "discretionary" and in the "health" category?

The opportunity is listed as discretionary funding in the health category, indicating it is a health-related federal funding opportunity administered by NIDA/NIH (as described in the listing).